AlzeCure Pharma
Alzecure Pharma: Comment on Study Results (Redeye)

2021-04-20 07:20
Yesterday, Alzecure Pharma announced positive results from its phase 1b study with drug candidate ACD440 in neuropathic pain. Redeye gives its first reflections to this news and raises Base Case.

info@redeye.se (Redeye.se)
Redeye AB - Redeye.se

AlzeCure Pharma - I dag

{point.key}

Marknadsöversikt

Stockholmsbörsen, OMXS30

I dag
-
Senast
-
{point.key}

Världsindex

Index +/- % Senast
DAX - -
Hang Seng - -
Nikkei - -

Valutor

Valuta +/- % Senast
USD/SEK - -
EUR/SEK - -
GBP/SEK - -
EUR/USD - -

Räntor

Ränta +/- % Senast
5-års ränta - -
10-års ränta - -

Råvaror

Råvara +/- % Senast
Guld - -
Silver - -
Koppar - -